Table 1 Baseline demographic and clinical characteristics
Sirolimus n = 33 (%) | Everolimus n = 91 (%) | |
|---|---|---|
Age in years, median (range) | 30 (19–59) | 29 (18–52) |
< 30 year | 16 (48) | 51 (56) |
≥ 30 year | 17 (52) | 40 (44) |
Sex | ||
Male | 10 (30) | 34 (37) |
Female | 23 (70) | 57 (63) |
LAM (female) | 5 (22) | 11 (19) |
≥ 1 Skin lesion | 31 (94) | 89 (98) |
SEGA | 2 (6) | 5 (5) |
Maximum diameter of target AML | ||
Median (range, cm) | 6.1 (3.5–16) | 8.1 (3.1–22) |
≥ 8 cm | 12 (36) | 48 (53) |
≥ 4 cm and < 8 cm | 16 (48) | 37 (41) |
≥ 3 cm and < 4 cm | 5 (15) | 6 (6) |
Number of target AML lesions (≥ 3 cm) | ||
1–2 | 14 (42) | 34 (37) |
3–4 | 19 (58) | 57 (63) |
Surgery/invasive procedure | 15 (45) | 36 (40) |
Renal embolisation | 5 (15) | 21 (23) |
Partial nephrectomy | 7 (21) | 10 (11) |
Nephrectomy | 6 (18) | 11 (12) |